Browse regulations

This regulation (43 CFR Part 3100) establishes the framework for oil and gas leasing on federal public domain and acquired lands under the Mineral Leasing Act. It defines which lands are available or exempt from leasing, sets acreage limitations per entity (246,080 acres in most states, 300,000 in Alaska districts), outlines requirements for options, transfers, and operations, and grants significant discretion to BLM 'authorized officers' to impose stipulations and modifications. It includes numerous special provisions for specific regions (Nevada, California, Minnesota, various national recreation areas) and coordinates with other agencies like Fish and Wildlife Service.

This regulation entrenches federal control over resource-rich land that properly belongs to states or private citizens under the Tenth Amendment, violating constitutional federalism. The complex maze of exemptions, stipulations, and discretionary authority creates barriers to entry favoring large corporations while crushing small operators with compliance costs—exactly the regulatory capture that Hayek warned against. The acreage limitations and unitization rules distort market signals and reduce supply. The entire federal leasing program represents centralized economic planning that cannot possibly account for local knowledge or opportunity costs, violating Mises' principle that only dispersed individuals can make rational economic calculations. Deleting this would return land management to states, reduce the hidden tax burden on Americans, and unleash competitive energy production.

BLM oil and gas leasing regulation defining terms, setting application procedures, establishing fee structures (fixed and case-by-case), mandating equal opportunity compliance, outlining appeals, and specifying enforcement provisions.

Complex procedures and non-refundable fees create barriers to entry, disproportionately burdening small operators and reducing competition. Unrelated EO 11246 mandates increase compliance costs. The unseen deadweight loss deters valuable leases, raising energy costs and concentrating market power. The program could be administered more efficiently with simplified, cost-based fees and minimal rules.

BLM regulation governing communications uses (cell towers, fiber, broadcast) on public lands, requiring permits, complex rent based on population and use type, exemptions, and annual certifications.

Complex rent calculation with 14 categories and population tiers creates high compliance costs, favors large incumbents, and distorts infrastructure deployment. The 270-day delay and annual certification add bureaucratic drag. Simpler competitive bidding or per-acre fees could achieve the same legitimate goals at a fraction of the cost.

This regulation implements the Medicare Part D Drug Inflation Rebate Program, requiring pharmaceutical manufacturers to pay rebates when drug prices increase faster than inflation. It defines 'Part D rebatable drugs' (approved drugs with certain exclusions), calculates an 'Annual Manufacturer Price' (AnMP) and compares it to an 'inflation-adjusted payment amount' based on a benchmark period. The rebate equals (AnMP - inflation-adjusted amount) × units dispensed, with various exclusions (low-cost drugs, shortages, 340B program drugs, supply chain disruptions).

This regulation imposes price controls disguised as rebates, interfering with voluntary market pricing and punishing manufacturers for price increases above inflation. It creates massive compliance complexity, distorts investment incentives, and likely reduces pharmaceutical innovation and availability. The unseen costs include fewer new drugs reaching market, potential shortages for marginally profitable medications, and shifted costs to other payers. It violates free enterprise principles by penalizing market success and assumes any price increase above CPI is problematic, ignoring legitimate cost drivers like R&D, production expenses, and regulatory burdens.

The regulation establishes the Medicare Part B Drug Inflation Rebate Program, requiring manufacturers to pay rebates when prices for single-source drugs and biologics increase faster than inflation. It calculates a per-unit rebate as the excess of the current 'specified amount' over an inflation-adjusted benchmark price based on the Consumer Price Index (CPI-U). The program excludes certain products like vaccines, generic drugs, and low-utilization drugs, and includes complex formulas for determining applicability and apportioning rebates among manufacturers.

The regulation imposes costly price controls that distort market incentives. By penalizing price increases above inflation, it reduces manufacturers' returns on investment, chilling innovation and R&D for new treatments. The complex compliance burden creates hidden costs passed to patients through higher prices elsewhere. Arbitrary inflation benchmarks ignore individual drug development costs and market dynamics, leading to misallocation of resources and potential shortages of older but essential medicines. The program exemplifies unconstitutional federal overreach into healthcare pricing, violating the Tenth Amendment's reservation of such matters to the states.

This regulation establishes the framework for addressing research misconduct (fabrication, falsification, plagiarism) in Public Health Service (PHS)-supported biomedical and behavioral research. It requires institutions receiving PHS funding to implement policies and procedures for investigating allegations, defines standards for findings of misconduct, and establishes HHS/ORI oversight authority including annual reporting requirements.

Taxpayers fund billions in health research annually; without federal standards, fraudulent or fabricated results could corrupt medical knowledge, endanger public health, and wastescarce resources. The regulation ensures due process while protecting the integrity of research that directly impacts life-or-death policy decisions. State or institutional self-regulation would create a patchwork with no uniform protection against fraud in federally-funded science.

Federal regulation establishing a two-tier system for opioid treatment programs: HHS Secretary approves private/nonprofit Accreditation Bodies, which then accredit OTPs. Includes rigorous standards, fees, reporting, conflict of interest rules, and oversight mechanisms. Certification required for OTPs to dispense medications for opioid use disorder.

This represents an unconstitutional federal incursion into healthcare regulation that belongs to states under the 10th Amendment. The accreditation bureaucracy imposes massive compliance costs that fall disproportionately on small treatment providers, reducing supply and access. The revolving door between accreditation bodies and OTPs creates regulatory capture risks. Federal oversight substitutes political control for market-driven quality signals, distorting incentives and potentially harming patients through reduced availability and higher costs. States are better positioned to craft responsive, cost-effective standards.

Regulation mandates reporting and recordkeeping for manufacturers, importers, and processors of nanoscale materials and 11-aminoundecanoic acid under TSCA Section 8(a). Requires detailed information including production volumes, uses, exposures, releases, and risk management practices, with exemptions for articles, byproducts, impurities, non-isolated intermediates, R&D, and small manufacturers.

Imposes significant compliance costs that fall heaviest on small chemical manufacturers, diverting resources from innovation to paperwork and creating barriers to entry. The regulation assumes federal preemptive oversight of all chemical information is necessary, violating Tenth Amendment federalism. Nanoscale materials are defined by arbitrary thresholds (1-100 nm, 1% by weight) capturing thousands of substances without demonstrated harm, creating a surveillance system that enables future regulatory expansion. Unseen consequences include stifled R&D, protected incumbents, and the chilling effect of mandatory reporting on technological development. Chemical safety is better governed by state tort law and market accountability that penalizes actual harm, not speculative risk.

Regulates vessel discharges (ballast water, graywater, bilgewater) to prevent water pollution and invasive aquatic species in U.S. waters. Applies to most commercial vessels with exceptions for military, recreational, small vessels, and permanently moored craft. Requires ballast water treatment systems, biofouling management plans, environmentally acceptable lubricants, and discharge minimization practices.

Imposes exorbitant compliance costs (ballast treatment systems, extensive documentation) that fall disproportionately on small operators, extends federal regulatory reach into state waters, creates safety risks from mandated ballast exchanges, reduces U.S. port competitiveness, and generates severe unintended consequences. Invasive species prevention could be achieved more efficiently through liability regimes and state coordination without this prescriptive federal mandate.

EPA facility response plan mandate for non-transportation onshore facilities storing CWA hazardous substances near navigable waters, based on threshold quantities, proximity, and substantial harm criteria. Requires detailed plans, EPA approval, recertification, and ongoing compliance with extensive definitions and EPA discretion.

Imposes crushing compliance costs (disproportionately on small businesses), inverts burden of proof, violates Tenth Amendment federalism, invites regulatory capture, and substitutes bureaucratic central planning for superior market mechanisms (insurance, tort liability, private response contracts). The hidden tax burden exceeds $14,000 per household and expands the regulatory labyrinth that already exceeds 185,000 pages, undermining economic liberty and rule of law.

This regulation establishes a complex bureaucratic process for the Postal Regulatory Commission to review and approve negotiated service agreements (NSA) between the Postal Service and private mailers. It defines procedures for adding NSAs to the competitive product list, requiring extensive financial modeling, public notifications, Commission findings, and compliance with 39 U.S.C. 3633. It includes streamlined options for umbrella products, non-published rates products, and standardized distinct products, each with their own detailed filing requirements.

This regulation imposes significant compliance costs to approve voluntary commercial contracts between willing parties. The extensive bureaucratic process—requiring financial models, multiple findings, public proceedings, and ongoing reporting—creates a hidden tax that distorts commercial relationships and favors large established players who can afford compliance. There is no evidence of market failure justifying government approval of these private agreements; the process merely enables regulatory capture and mission creep while delaying innovation in postal service pricing. The Commission's role in pre-approving contracts assumes government wisdom superior to negotiators, contradicting free market principles. These costs ultimately harm consumers through higher prices and reduced service options.

These regulations implement the Freedom of Information Act for the Postal Regulatory Commission, setting procedures for submitting, processing, and appealing requests for agency records, including proactive disclosure requirements, electronic reading rooms, fee schedules, and rules for handling confidential or exempt materials.

Americans would be worse off because these regulations provide the essential procedural framework that makes FOIA's transparency mandate effective. Without standardized processes for requests, appeals, and proactive disclosure, the public would face unpredictable barriers to accessing Commission records, undermining accountability and enabling bureaucratic secrecy—the antithesis of limited government. The rules achieve FOIA's goals in a way that ad hoc agency guidance could not, ensuring consistent, timely, and open access to government information.

The Veteran and Spouse Transitional Assistance Grant Program (VSTAGP) authorizes VA to provide grants to eligible organizations (states, localities, universities, tribes, nonprofits, faith-based groups) to deliver employment transition services—including resume assistance, interview training, and job recruitment—to veterans and their spouses. Grants cover up to 50% of costs for up to 5 years, require matching funds, and impose extensive reporting, audit, and compliance obligations consistent with 2 CFR 200.

This program federalizes a local workforce development function properly handled by private charities, educational institutions, state/local agencies, or the existing GI Bill. It imposes significant compliance burdens on grantees, distorts service delivery toward grant requirements rather than veteran outcomes, and adds to the $2 trillion national regulatory burden while duplicating services already available. The unseen costs include bureaucratic overhead, regulatory capture risks in scoring, crowding out of private philanthropy, and Tenth Amendment federalism violations.

Delegates various authorities within the Department of Veterans Affairs to specific positions, including subpoena power, oath administration, document certification, fee setting, claims handling, and employment discrimination complaint adjudication.

Internal delegations are necessary for efficient agency operations. Removal would create uncertainty and procedural chaos, harming veterans who rely on VA services, without reducing any public compliance burden.

This regulation establishes internal procedures for the Patent Trial and Appeal Board (PTAB), governing pre-issuance circulation of draft decisions, communications restrictions with leadership, panel assignments, and transparency requirements. It prohibits the Director, Deputy Director, and Commissioners from communicating with panels about decisions before issuance (unless on the panel), restricts Management Judge influence unless invited by a panel member, requires public written guidance only, and affirms panels' final authority over decisions.

This rule enforces critical internal constraints that protect judicial independence and the rule of law within the patent system. It prevents political interference and regulatory capture by prohibiting backdoor communications from agency leadership to decision-making panels, requires all binding guidance to be public (eliminating secret rules), and affirms panel autonomy. These guardrails safeguard property rights—patents are legally protected assets—by ensuring impartial adjudication. Eliminating this would create risk of politicized, opaque, or captured decision-making that harms inventors and innovation, with no alternative mechanism providing equivalent transparency and independence protections.